Actively Recruiting
Study of Intravenous Lidocaine Added to Standard Care to Reduce Opioid Use During Severe Vaso-Occlusive Crisis in Adults with Sickle Cell Disease
Led by Nantes University Hospital · Updated on 2026-09-09
104
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding lidocaine to the standard pain management can reduce the total amount of opioids used during severe vaso-occlusive crisis in adults with sickle cell disease. This Phase 3 trial focuses on patients admitted to the Intensive Care Unit due to painful vaso-occlusive crisis or acute chest syndrome related to sickle cell disease, aiming to improve pain control and reduce opioid consumption. Participants are randomly assigned to receive either intravenous lidocaine or a placebo alongside standard care. The lidocaine is given as a bolus dose of 1.5 mgkg over 30 minutes followed immediately by a continuous infusion of 1 mgkgh for 72 hours. The placebo group receives the same volume and infusion schedule using sodium chloride solution. Both treatments are administered through a peripheral or central venous catheter. During the study, participants are closely monitored for opioid use during their ICU stay, pain levels, length of ICU and hospital stay, and any complications related to vaso-occlusive crisis. Researchers also assess quality of life, safety of lidocaine infusion, and rates of readmission within 28 days. The main outcome is opioid consumption expressed in morphine milligram equivalents from randomization until ICU discharge, with follow-up for up to 28 days.
CONDITIONS
Brief Title
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
Research Team
M
Maïté AGBAKOU
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here